Nutrien's record quarter is a potash-price bet dressed as a food-security story

---

On April 28, 2026, Nutrien Ltd. published a first quarter it described in the language of triumph: record potash sales volumes, adjusted EBITDA up 30% to $1.105 billion, total revenue of $6.0 billion, up nearly 19% year over year. The headline numbers were genuinely strong, and management was entitled to take a bow. Then the stock fell roughly 7.36% — to the low $70s — in the session that followed. That gap, between the press-release adjectives and the market's verdict, is the whole story. It is the gap a forensic reader lives inside. Because when a company reports a "record" and the equity sells off, the market is usually telling you something the income statement is structured to obscure: that the good number was a loan from a commodity cycle, not a payment from a durable franchise.

This is the thesis. Nutrien is the world's largest potash producer and a vertically integrated agricultural input giant — a real business with real assets and a genuinely advantaged ore body. But it is, at its economic core, a price-taker. Its earnings are a leveraged bet on three benchmarks it does not control: the offshore price of potash, the spread between natural gas and nitrogen, and the volume of fertilizer the world's farmers can afford to buy. When those benchmarks rise, as they did into Q1 2026, the income statement looks like a growth company. When they collapse, as they did from the April 2022 peak of $1,202 a tonne to roughly $310 by late 2023, the same income statement looks like a wreck. The company is constant. The cycle is everything. And the marketing of that cycle as a secular "food security" megatrend is the loophole this piece is written to close.

The adjustment gap: $0.27 of GAAP, $0.51 of story

Start where the company would rather you finished. Nutrien's Q1 2026 GAAP net earnings were $139 million, or $0.27 in diluted earnings per share. The number it puts in lights is adjusted net earnings of $0.51 per share — almost exactly double. That spread is not a rounding artifact. It is the difference between what the business actually earned under generally accepted accounting principles and what management asks you to treat as the "real" run-rate after stripping out items it deems non-representative: facility closure impacts, asset impairments, foreign-exchange swings on its debt, share-based compensation revaluations, and the rest of the adjusted-EBITDA toolkit.

There is a defensible logic to some of these adjustments. A non-cash foreign-exchange revaluation on long-term debt genuinely does not reflect a quarter's operating health. But the habit of anchoring the entire investment narrative to a metric that doubles the GAAP figure deserves scrutiny — because the adjustments are not symmetric over time, and they are not free. Facility closures are real cash decisions with real consequences. Impairments are the delayed admission that capital was deployed into assets that did not earn their keep. When a company routinely earns $0.27 under GAAP and reports $0.51 "adjusted," the burden of proof sits with the adjustment, not the GAAP line. And in a capital-intensive miner, the GAAP line — which absorbs the depreciation of the very ore bodies and plants that generate the revenue — is closer to the economic truth than an EBITDA figure that flatters the business by pretending the plants were free.

Adjusted EBITDA of $1.105 billion sounds like a fortress. But Nutrien carries roughly $12.6 billion of total debt — $2.77 billion short-term and $9.86 billion long-term — against which that EBITDA must service interest, fund $2.0 to $2.1 billion of guided 2026 capital expenditure, cover $264 million of declared dividends, and still leave something for shareholders. EBITDA is not earnings. In a business this capital-hungry, the distance between the two is the whole game, and it is precisely the distance the adjusted metric is engineered to make you forget.

The price-taker's tell: 21% on potash, 13% on nitrogen

Here is the forensic core. Look at what drove the record quarter, line by line, and you find a company that did almost nothing different — the market did it for them.

Potash adjusted EBITDA rose to $578 million. The driver, per the company's own disclosure, was an average net selling price up 21% to $264 per tonne, "driven by higher global benchmark prices and favorable affordability in key offshore markets." Read that sentence again. Higher global benchmark prices. Nutrien did not invent a product, win a contract, or build a moat last quarter. The price of a commodity it digs out of the ground went up 21%, and the earnings followed. That is the literal definition of a price-taker: a producer whose realized price is set by a global benchmark in which any single seller — even the largest — is a participant, not an author.

Nitrogen tells the identical story from the other direction. Nitrogen adjusted EBITDA was $482 million despite a 5% decline in volumes — because realized prices rose 13% to $381 per tonne. Volumes down, earnings up, on price alone. Nitrogen's economics are even more nakedly a spread trade: ammonia is manufactured from natural gas, so nitrogen margin is the gap between the price of urea and the cost of the gas feedstock. Nutrien controls neither input. It is short gas and long urea, and last quarter both legs moved its way. Next quarter they may not.

When two of your three engines run on prices you do not set, you are not a growth company that happens to be in commodities. You are a commodity exposure with a corporate-headquarters overlay. The distinction is not academic. A growth company widens its margins by doing something its competitors cannot — a process, a network, a brand, a technology that compounds. A price-taker widens its margins only when the benchmark moves, and the benchmark moves for reasons that have nothing to do with management's effort and everything to do with sanctions, weather, freight, and the marginal Belarusian tonne. The "record" volumes are real and creditable — 3.51 million tonnes of potash is operational excellence. But volume times a benchmark price you don't control is still a benchmark bet. The forensic question is never "did earnings grow?" It is "what grew them, and can it recur on the company's own merit?" Here, the honest answer is: the benchmark grew them, and the benchmark will take them away on its own schedule.

The 2022 ghost: a $1,202 peak, a $310 present

Nothing exposes the price-taker frame like the long arc of potash itself. In April 2022, in the panic following Russia's invasion of Ukraine and the sanctioning of Belarusian potash, the benchmark spiked to roughly $1,202 per tonne. Nutrien printed the best numbers in its history, opened the spending taps to expand potash capacity, and the bull case crowned it a structural winner of a food-insecure world. By the end of 2023, that same potash was changing hands near $311 a tonne — a roughly 74% collapse. In spring 2026, MOP in the U.S. Corn Belt sits around $310 to $380 a ton, largely flat to up perhaps 10% year over year.

Sit with those three data points. $1,202. $311. ~$340. That is not the price chart of a secular growth franchise; it is the price chart of a commodity doing what commodities do — spiking on a supply shock, crashing as supply normalizes, and grinding in a band defined by the marginal cost of production and the affordability of the world's farmers. Nutrien's earnings traced the same arc: a 2022 windfall, a brutal 2023–2024 normalization, and now a 2026 recovery off a low base. Full-year 2025 net earnings were $2.30 billion on $19.59 billion of revenue. That is a fine year. But it is a cyclical fine year, sitting on a curve, not a secular compounding base.

The danger in the current narrative is that the Q1 2026 rebound is being read as the start of a new structural up-leg rather than as a mid-cycle bounce — partly fueled, by the company's and analysts' own framing, by geopolitical risk premia: Middle East tensions threatening roughly 40% of global urea exports, and lingering Belarus and Russia supply uncertainty. Geopolitical risk premia are the most ephemeral earnings of all. They evaporate the moment the headlines fade, and they leave the producer holding the expanded cost base it built when the prices looked permanent.

The denominator illusion: "record" against an easy base

The word "record" is doing heavy lifting, and it should be inspected. Record potash volumes — true, and operationally impressive. But the 30% jump in adjusted EBITDA and the 1,090% jump in net income attributable to shareholders are measured against a Q1 2025 base that was itself depressed by the post-2022 price trough. When you grow off a cyclical bottom, percentage gains look spectacular and tell you almost nothing about the level. A 1,090% increase from a trough is arithmetic, not alchemy. The relevant comparison is not "up 30% on last year" but "where does this sit versus the 2022 peak and versus mid-cycle?" — and on that axis, the quarter is a recovery, not a breakout.

This is the denominator illusion in its purest form. Choose a low enough base and any cyclical can be dressed as a growth stock for a quarter or two. The discipline is to normalize across the cycle. Across the cycle, Nutrien's potash earnings oscillate with a benchmark that has ranged from roughly $300 to $1,200 in four years. No multiple of "growth" applied to a single up-quarter changes that range. The base effect is a storyteller's friend and a forensic analyst's first suspect.

The cash-flow asterisk: negative $851 million

Behind the EBITDA glow sits a number the press release does not lead with: cash from operations in Q1 2026 was negative $851 million. Management attributes this — fairly — to working-capital seasonality. The Retail business builds inventory ahead of the spring planting season, and the cash unwinds later in the year. This is a normal pattern for an ag-input distributor, and it would be unfair to call it distress.

But it is fair to note the structural point it illustrates. Nutrien's earnings quality is hostage not only to commodity prices but to a working-capital cycle that can swing a billion dollars a quarter, and to a Retail segment whose Q1 adjusted EBITDA of $108 million — even after doubling year over year — is a thin sliver of the company's total. The fortress EBITDA and the negative operating cash flow describe the same company in the same quarter. Only one of them appears in the headline. A reader who anchors on adjusted EBITDA and never reaches the cash-flow statement has been told a story, not shown a business.

The miss inside the beat

There is one more tell buried in the reaction. Nutrien's $0.51 adjusted EPS beat the Zacks consensus of $0.48 on one tally, yet on another widely cited forecast it missed a $0.53 expectation, and the stock sold off either way. Revenue of roughly $6.05 billion blew past a $5.35 billion estimate — a 12.9% beat — and still the equity fell. When a company beats on revenue, posts record volumes, and the stock drops 7%, the market is not confused. It is discounting. It has looked at the same potash price chart this piece has, recognized the geopolitical risk premium as transient, weighed the Q4 2025 miss ($0.83 versus $0.92 expected) still fresh in memory, and concluded that the "record" is the good part of the cycle being marked as the new normal. Priced-for-perfection cyclicals do not get rewarded for perfection; they get sold on the first hint that perfection was the cycle, not the company.

What the bulls genuinely get right

It would be dishonest to leave the bull case as a straw man, because parts of it are genuinely strong, and a fair forensic account must concede them precisely.

First, the moat is real, not rhetorical. Nutrien sits on some of the lowest-cost, longest-life potash reserves on earth, in Saskatchewan, with brownfield expansion optionality that a new entrant cannot replicate — building greenfield potash capacity takes the better part of a decade and billions of dollars. As the marginal-cost, low-cost producer, Nutrien survives troughs that bankrupt higher-cost rivals and harvests the peaks. That is a durable structural advantage, and it is the single best argument for owning the stock through a cycle.

Second, the integration is a genuine stabilizer. Nutrien's Retail arm — the largest agricultural retailer in North America — generated $108 million of adjusted EBITDA in Q1 and is guided to $1.75–$1.95 billion for the full year, with earnings that are far less volatile than upstream fertilizer prices. That distribution franchise, with its proprietary products and crop-input services, smooths the commodity swing and gives Nutrien a downstream toehold a pure miner lacks.

Third, the demand floor is real. The food-security narrative is overcooked as a valuation argument, but the underlying biology is sound: crops remove nutrients from soil every harvest, and potassium in particular cannot be synthesized or substituted — it must be replaced. That creates a genuine consumption floor under potash demand that does not exist for most commodities. Demand may be cyclical, but it does not go to zero, and it grows with global population and protein consumption over decades.

Fourth, management has executed on cost and capital discipline. The company cut controllable cash costs, lowered capital expenditure versus prior targets, returned $2.30 billion of net earnings in 2025, and is buying back stock and paying a $0.55 quarterly dividend. That is shareholder-friendly stewardship of a cyclical balance sheet, and it is the right behavior for the asset.

None of this is in dispute. The dispute is narrower and sharper: whether a genuinely advantaged, well-run, low-cost cyclical should be valued and narrated as a secular growth compounder. The moat protects the downside; it does not convert a price-taker into a price-maker. Conceding the moat and conceding the secular-growth multiple are two different acts, and the bull case too often smuggles the second in on the back of the first.

The food-security loophole

The phrase doing the most damage to clear thinking is "food security." It is true, important, and almost entirely beside the point of how Nutrien's stock should be priced. The world will need fertilizer for as long as it grows crops — granted. But "the world needs the product" has never been sufficient to make a commodity producer a good investment. The world needs oil, copper, steel, and wheat too, and the producers of all of them trade as cyclicals, on mid-cycle multiples, precisely because needing the product and pricing the product are different things. Demand security is not price security. Nutrien can sell every tonne it makes and still see its earnings halve when the benchmark halves, exactly as happened from 2022 to 2024.

The loophole is the elision between the two. "Food security" smuggles a secular-growth multiple onto an asset whose cash flows are dictated by a volatile, mean-reverting benchmark. The correct frame is the boring one: Nutrien is a high-quality, low-cost cyclical that should be bought when the benchmark is depressed and earnings are trough, and trimmed when the benchmark is elevated and the press releases say "record." Buying the record is buying the top of the price-taker's range and calling it growth.

The kicker

Nutrien is not a fraud, not a house of cards, not a short into oblivion. It is something subtler and, for the long-term holder, more dangerous: a genuinely excellent business being sold under a genuinely misleading label. The potash is low-cost and the reserves are long-life and the retail arm is real — and none of it changes the fact that the income statement is a leveraged wager on three prices the company cannot set, marked at a moment when all three happened to be rising. The $139 million of GAAP net earnings is the truth; the $0.51 adjusted is the marketing; the $1,202-to-$310 potash chart is the memory the market has and the press release hopes you've lost. Strip the food-security poetry and the adjustment cosmetics, and what remains is a cyclical at a mid-cycle price being narrated as a compounder at the top of its range — which is the exact moment such stories are most flattering and least true.

Nutrien sells a product the world cannot live without and a stock the world keeps mistaking for the thing it digs out of the ground; the rock is permanent, the price is not, and the day they call it a record is the day to ask who set it.